Agios Pharmaceuticals Ownership | Who Owns Agios Pharmaceuticals?
Agios Pharmaceuticals Ownership Summary
Agios Pharmaceuticals is owned by 108.74% institutional investors, 1.09% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.98% of AGIO shares. BB Biotech AG Ord is the top mutual fund, with 6.34% of its assets in Agios Pharmaceuticals shares.
AGIO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Agios Pharmaceuticals | 108.74% | 1.09% | -9.83% |
| Sector | Healthcare Stocks | 35.56% | 12.08% | 52.36% |
| Industry | Biotech Stocks | 35.43% | 12.01% | 52.56% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 6.46M | 10.98% | $239.58M |
| Farallon capital management | 5.68M | 9.80% | $192.29M |
| Vanguard group | 5.59M | 9.62% | $152.28M |
| Blackrock | 4.86M | 8.55% | $209.52M |
| Bellevue group | 3.71M | 6.41% | $149.11M |
| State street | 3.53M | 6.01% | $131.14M |
| Armistice capital | 2.72M | 4.68% | $91.88M |
| D. e. shaw | 2.68M | 4.62% | $90.70M |
| Paradigm biocapital advisors lp | 2.67M | 4.61% | $107.32M |
| Lynx1 capital management lp | 2.61M | 4.50% | $88.35M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Lynx1 capital management lp | 2.61M | 13.96% | $88.35M |
| Caligan partners lp | 1.13M | 5.95% | $45.41M |
| Commodore capital lp | 2.34M | 4.58% | $93.86M |
| Cutter capital management, lp | 301.62K | 4.06% | $9.91M |
| Foresite capital management vi | 525.00K | 3.86% | $17.76M |
| Bioimpact capital | 1.31M | 3.41% | $44.19M |
| Bellevue group | 3.71M | 3.10% | $149.11M |
| Paradigm biocapital advisors lp | 2.67M | 3.05% | $107.32M |
| Exome asset management | 125.06K | 2.19% | $4.23M |
| Knott david m jr | 93.06K | 1.87% | $3.15M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Lynx1 capital management lp | 2.61M | 13.96% | 2.53M |
| Paradigm biocapital advisors lp | 2.67M | 3.05% | 1.53M |
| T. rowe price investment management | 1.49M | 0.03% | 1.49M |
| D. e. shaw | 2.68M | 0.05% | 843.98K |
| Blackrock funding, inc. /de | 6.46M | 0.00% | 701.04K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Macquarie group | - | - | -1.96M |
| Jefferies financial group | - | - | -1.50M |
| Tcg crossover management | - | - | -1.18M |
| Bvf inc/il | - | - | -1.07M |
| Polar capital | - | - | -1.00M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard fiduciary trust | 382.02K | 0.00% | 382.02K | $12.92M |
| Arrowstreet capital, limited partnership | 250.46K | 0.00% | 250.46K | $8.47M |
| Schonfeld strategic advisors | 200.06K | 0.05% | 200.06K | $6.77M |
| Eversept partners, lp | 200.00K | 0.36% | 200.00K | $6.77M |
| Axa investment managers | 177.68K | 0.02% | 177.68K | $7.13M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -1.00 |
| Dinuzzo private wealth | -1.00 |
| Riggs asset managment | -3.00 |
| Global financial private client | -3.00 |
| Hfm investment advisors | -3.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 246 | -3.91% | 63,038,205 | 2.90% | 108 | 0.98% | 123 | -13.99% | 76 | 7.04% |
| Dec 31, 2025 | 165 | -31.82% | 34,473,117 | -45.71% | 59 | 0.49% | 89 | -24.58% | 49 | -28.99% |
| Sep 30, 2025 | 229 | 9.05% | 60,859,306 | 3.40% | 105 | 1.02% | 111 | 4.72% | 67 | -6.94% |
| Jun 30, 2025 | 217 | -3.56% | 61,654,515 | 3.33% | 106 | 0.99% | 108 | -5.26% | 76 | 5.56% |
| Mar 31, 2025 | 223 | -4.29% | 59,949,912 | 0.23% | 104 | 0.95% | 113 | -12.40% | 71 | 2.90% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BB Biotech AG Ord | 3.71M | 6.34% | 124.59K |
| State Street® SPDR® S&P® Biotech ETF | 1.97M | 3.30% | 4.52K |
| Vanguard Morn Total Stk Mkt Idx Investor | 1.89M | 3.18% | 718.00 |
| Vanguard Total Stock Mkt Idx Inv | 1.89M | 3.18% | 718.00 |
| Vanguard US Total Market Shares ETF | 1.79M | 3.12% | 2.35K |
| Nomura US Small Cap Core Equity | 1.70M | 2.85% | 513.26K |
| Nomura Small Cap Core I | 1.70M | 2.84% | 550.78K |
| iShares Russell 2000 ETF | 1.51M | 2.52% | -26.78K |
| Macquarie Small Cap Core I | 1.43M | 2.46% | -107.41K |
| Delaware Small Cap Core I | 1.38M | 2.42% | -8.55K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 04, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $914.40K |
| Jul 01, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $150.50K |
| Apr 02, 2026 | Burns James William | Chief Legal Officer | Sell | $113.85K |
| Apr 02, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | $102.05K |
| Apr 02, 2026 | Jones Cecilia | Chief Financial Officer | Sell | $109.02K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 2 |
| 2026 Q2 | - | 7 |
| 2026 Q1 | - | 22 |
| 2025 Q4 | - | 11 |
| 2025 Q3 | - | 9 |
AGIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools